WOBURN, Mass.--(BUSINESS WIRE)--Feb. 1, 2006--ArQule, Inc. (NASDAQ: ARQL) today announced the enrollment and successful dosing of the first patient in a Phase 1 clinical trial with ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase.
